LXM 2
Alternative Names: LXM-2; LXM.2Latest Information Update: 06 Dec 2024
Price :
$50 *
At a glance
- Originator Laxxon Medical
- Class Obesity therapies
- Mechanism of Action Glucagon-like peptide-1 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Diabetes mellitus; Metabolic syndrome; Obesity
Highest Development Phases
- Preclinical Diabetes mellitus; Metabolic syndrome; Obesity
Most Recent Events
- 14 Oct 2024 Preclinical trials in Diabetes mellitus in USA (PO) (Laxxon Medical pipeline, October 2024)
- 14 Oct 2024 Preclinical trials in Metabolic syndrome in USA (PO) (Laxxon Medical pipeline, October 2024)
- 14 Oct 2024 Preclinical trials in Obesity in USA (PO) (Laxxon Medical pipeline, October 2024)